Remnant cholesterol, the cardiovascular-kidney-metabolic syndrome, and cardiovascular disease: lessons from CHARLS
- PMID: 40554599
- DOI: 10.1093/eurjpc/zwaf345
Remnant cholesterol, the cardiovascular-kidney-metabolic syndrome, and cardiovascular disease: lessons from CHARLS
Conflict of interest statement
Conflict of interest: M.M. has nothing to declare. R.D.S. has received honoraria related to consulting, research, and speaker activities from Amgen, Arrowhead, Daiichi Sankyo, Esperion, Ionis, Eli Lilly, MSD, Novo-Nordisk, Novartis, PTC Therapeutics Torrent, Sanofi/Regeneron, and Ultragenyx.
Comment on
-
Association between remnant cholesterol and the risk of cardiovascular-kidney-metabolic syndrome progression: insights from the China health and retirement longitudinal study.Eur J Prev Cardiol. 2025 Sep 22;32(13):1157-1165. doi: 10.1093/eurjpc/zwaf248. Eur J Prev Cardiol. 2025. PMID: 40272444
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
